VRTX241025C620000
- 0.05
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $535
Piper Sandler Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $490 to $600
Vertex Pharmaceuticals' Promising Market Position and Opioid-Sparing Solution Drive Buy Rating
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $490 to $600
Optimistic Buy Rating for Vertex Pharmaceuticals Amid Promising VX-548 Developments
Vertex Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Korro Bio (KRRO) and Vertex Pharmaceuticals (VRTX)
Analysts Are Neutral on These Healthcare Stocks: CVS Health (CVS), Vertex Pharmaceuticals (VRTX)
Cautious Hold on Vertex Pharmaceuticals Amidst Limited New Insights and Awaited Data
Vertex Pharmaceuticals: Strategic Growth and Promising Drug Development Drive Buy Rating
Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
UBS Initiates Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $562
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Initiated With a Sector Perform at Scotiabank
Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
Vertex Pharmaceuticals Analyst Ratings
BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $541
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $473 From $474